Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model

Resiquimod is an immunopotent toll-like receptor 7/8 agonist with anti-tumor activity. Despite being potent against skin cancers, it’s poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Adv Healthc Mater
Autores principales: Kakwere, Hamilton, Zhang, Hua, Ingham, Elizabeth S., Nura-Raie, Marina, Tumbale, Spencer K., Allen, Riley, Tam, Sarah M., Wu, Bo, Liu, Cheng, Kheirolomoom, Azadeh, Fite, Brett Z., Ilovitsh, Asaf, Lewis, Jamal S., Ferrara, Katherine W.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153207/
https://ncbi.nlm.nih.gov/pubmed/33646600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202100008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares